Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.
Optimizing Retinal Care with Next-Generation Anti-VEGF Agents: Insights from Clinical Practice
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME.
Advertisement
Advertisement
Trending on Modern Retina
1
FLORetina 2025: Industry advances front and center at FLORetina Congress
2
EyePoint receives second consecutive positive recommendation from DSMC
3
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
4
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
5
